Stock Events

Stock Events

Santhera Pharmaceuticals 

CHF16.68
31
-CHF0.11-0.67% Today

Statistics

Day High
16.68
Day Low
16.68
52W High
18.26
52W Low
6.15
Volume
900
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

28AprExpected
Q1 2023
Q2 2023
Q1 2024
Q2 2024
Q1 2025
Q2 2025
Next
-3.03
-2.02
-1.01
0
Expected EPS
N/A
Actual EPS
N/A

Financials

-107.3%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
78.23MRevenue
-83.95MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 0QN1.LSE. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sarepta Therapeutics
SRPT
Mkt Cap2.26B
Sarepta Therapeutics focuses on the discovery and development of RNA-based therapeutics for the treatment of rare neuromuscular diseases, similar to Santhera's focus on Duchenne muscular dystrophy and other mitochondrial and neuromuscular diseases.
PTC Therapeutics
PTCT
Mkt Cap5.99B
PTC Therapeutics is involved in the development of drugs for the treatment of rare disorders, including Duchenne muscular dystrophy, which is a direct competition to Santhera's product pipeline.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.51B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions, including rare genetic disorders that overlap with Santhera's target market.
Solid Biosciences
SLDB
Mkt Cap789.1M
Solid Biosciences is focused on developing therapies for Duchenne muscular dystrophy, directly competing with Santhera's efforts in the same area.
Wave Life Sciences
WVE
Mkt Cap1.41B
Wave Life Sciences is working on genetically defined diseases, including Duchenne muscular dystrophy, positioning it as a competitor in the same niche as Santhera.
CRISPR Therapeutics
CRSP
Mkt Cap5.57B
CRISPR Therapeutics is engaged in the development of gene-based therapies for serious diseases, including treatments that could potentially compete with Santhera's pipeline for neuromuscular and mitochondrial diseases.
Editas Medicine
EDIT
Mkt Cap341.57M
Editas Medicine operates in the genome editing field, aiming to develop therapies for a range of serious diseases, including those in Santhera's focus area, making it a competitor.
Novartis
NVS
Mkt Cap293.34B
Novartis is a large pharmaceutical company with a broad portfolio that includes treatments for neuromuscular diseases, among others, competing with Santhera on a larger scale.
Pfizer
PFE
Mkt Cap156.77B
Pfizer is a global biopharmaceutical company with a diverse portfolio, including research in rare diseases, which could potentially compete with Santhera's niche market.

About

Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company's lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
Show more...
CEO
Dr. Thomas Meier Ph.D.
Employees
78
Country
Switzerland
ISIN
CH1276028821

Listings

OTC Link
US
SPHDF
MU
DE
S3F0.MU
STU
DE
S3F0.STU
F
DE
S3F0.F

0 Comments

Share your thoughts

FAQ

What is Santhera Pharmaceuticals stock price today?▼
The current price of 0QN1.LSE is CHF16.68 CHF — it has decreased by -0.67% in the past 24 hours. Watch Santhera Pharmaceuticals stock price performance more closely on the chart.
What is Santhera Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Santhera Pharmaceuticals stocks are traded under the ticker 0QN1.LSE.
When is the next Santhera Pharmaceuticals earnings date?▼
Santhera Pharmaceuticals is going to release the next earnings report on April 28, 2026.
What were Santhera Pharmaceuticals earnings last quarter?▼
0QN1.LSE earnings for the last quarter are -3.03 CHF per share, whereas the estimation was N/A CHF resulting in a N/A surprise. The estimated earnings for the next quarter are N/A CHF per share.
What is Santhera Pharmaceuticals revenue for the last year?▼
Santhera Pharmaceuticals revenue for the last year amounts to 78.23M CHF.
What is Santhera Pharmaceuticals net income for the last year?▼
0QN1.LSE net income for the last year is -83.95M CHF.
How many employees does Santhera Pharmaceuticals have?▼
As of April 24, 2026, the company has 78 employees.
In which sector is Santhera Pharmaceuticals located?▼
Santhera Pharmaceuticals operates in the Manufacturing sector.
When did Santhera Pharmaceuticals complete a stock split?▼
The last stock split for Santhera Pharmaceuticals was on July 03, 2023 with a ratio of 1:10.
Where is Santhera Pharmaceuticals headquartered?▼
Santhera Pharmaceuticals is headquartered in Pratteln, Switzerland.